EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CKD screening: urinary albumin or uDKK3 or both?

Stefan Neuhaus, Danilo Fliser iD, Stefan Schunk

Nephrology Dialysis Transplantation · 05.08.2026

DOI: 10.1093/ndt/gfag166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 05.08.2026. Verfasst von Stefan Neuhaus und 2 weiteren Autor:innen. Beteiligte Einrichtung: Saarland University Medical Center, Clinic for Internal Medicine IV, Homburg/Saar, Germany. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, INST.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 750 million people worldwide suffer from chronic kidney diseases (CKDs)—a leading cause of cardiovascular morbidity and premature mortality—but early identification of progressive kidney function decline in patients at risk is still a challenge. CKD diagnosis relies on estimated glomerular filtration rate and albuminuria screening, primarily reflecting glomerular injury. Nevertheless, in a substantial proportion of affected subjects progressive CKD initially remains undetected, since kidney function deteriorates through ongoing tubulointerstitial injury without significant albuminuria, a condition known as “nonalbuminuric” CKD. Urinary Dickkopf-3 (uDKK3) has emerged as an innovative biomarker of progressive CKD, which is expressed by proximal tubular epithelial cells as a response to continuing injury. It is secreted into the urine, where it signals ongoing fibrogenic activity within the kidney. Clinical studies across a broad range of CKD etiologies—in adults and children alike—have shown that elevated uDKK3 significantly improved detection and prediction of progressive CKD after adjustment for established CKD risk markers including albuminuria. Moreover, in primarily nonalbuminuric populations, e.g. those with type 2 diabetes and patients with heart or lung diseases, uDKK3 identifies high-risk individuals for future decline of kidney function. These findings support the hypothesis that CKD progression follows different pathways of mainly glomerular or tubulointerstitial injury. It is therefore plausible to use complementary biomarkers for CKD screening—albuminuria and uDKK3–each reflecting a distinct biological dimension of kidney injury. We discuss the limitations of albuminuria screening and propose a framework for integrating tubular markers like uDKK3 into future CKD screening strategies.

Schlagwörter

Stichwörter der Autor:innen

CKDDKK3albuminuriaeGFRprogression

Autor:innen und Institutionen

  • Saarland University Medical Center, Clinic for Internal Medicine IV, Homburg/Saar, Germany.

ORCID-Profile: Danilo Fliser

Förderung

  • Deutsche Forschungsgemeinschaft
  • INST

Zitieren

APA

Neuhaus, S., Fliser, D., & Schunk, S. (2026). CKD screening: urinary albumin or uDKK3 or both?. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag166

Vancouver

Neuhaus S, Fliser D, Schunk S. CKD screening: urinary albumin or uDKK3 or both?. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag166

BibTeX
@article{Neuhaus2026,
  author = {Neuhaus, Stefan and Fliser, Danilo and Schunk, Stefan},
  title = {CKD screening: urinary albumin or uDKK3 or both?},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag166}
}
Kostenlos starten →